STUDresearch · Non-peptide
ACP-105
Also known as
ACP105 · ACP 105 · Acadia SARM ACP-105 · non-steroidal SARM ACP-105 · 2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile · CAS 1048998-11-3
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
Oral
SARMs (adjacent discourse)
Systemic oral SARM — muscle/bone selectivity comes from preclinical work, not local targeting or proof of a safe steroid replacement.
What people say
ACP-105 is an oral SARM discussed for lean recomp, pumps and a dry look. The “milder than LGD/RAD” reputation comes from sparse logs and preclinical selectivity—not established human safety or physique trials.
Doses people talk about
No safety-validated physique dose. Single-dose versus total-daily amounts and co-use must remain distinct.
How it may feel
Reports range from energy, pumps and strength gains to no early change, weaker lifts or a wired-but-tired feeling. Headache and disrupted sleep appear; one hospital-evaluation account later added antibiotics and intestinal-blockage context.
Common oral chart band~10–20 mg/day oral
Lower charts describe ~10–12 mg/day. Once-daily versus divided totals is disputed; detailed split examples remain below. These are reports, not an entry dose.
Higher chart / log amounts~15–25 mg/day oral
Some comparisons extend to ~15–30 mg/day, with occasional ~25–30 mg/day ceiling talk. Higher exposure brings suppression and androgenic-side concerns; not an escalation target.
Sparse female discussionSingle-digit to ~5–10 mg/day oral
The same blogs include an unvalidated “never over ~15 mg” rule and shorter ~6–8-week talk. Virilization risk is not removed by a low amount.
Half-life & effect duration
- Half-life in the body
- Community / vendor estimateAbout 12–16 hours
- Computer predictionAbout 1.18 hours
- Liver-cell stability testAbout 5 hours
- Felt duration people report
- One oral logAbout 8 hours of perceived coverage, followed by tiredness
- Other accountsImprovement, no effect, or worse strength
Cycles people discuss
6–8 weeks dominates chart talk; 4–6-week stops and longer 8–12 or 8–13-week templates also appear. Time-off, PCT and on-cycle enclomiphene are debated, with no ACP-specific validated recovery calendar.
Timing
Once-daily versus split use is disputed. Logs mention morning/later doses, roughly 8-hour spacing or ~30 minutes pre-workout; sleep effects matter. Cell/model half-lives do not validate these routines.
Stacks
Ostarine, AC-262, Cardarine and sometimes stronger SARMs appear in stack talk. Enclomiphene/PCT and support supplements add confounding; premixed ratios and claimed protection remain unverified.
Watch for
HPTA suppression: Expected class risk with dose and duration; community markers include reduced morning erections, libido drop, mood, and energy — documented subjectively even in “mild” partial-agonist framing.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No measured human half-life established by the checked evidence.
The ~1.18-hour ADMETlab output is a prediction. Older notes separately quote cell-culture stability and 12–16-hour vendor lore; none becomes volunteer PK here.
This bounded source check does not establish a universal absence of human data. Model, cell, animal and subjective clocks are not interchangeable.
- ACP-105 integrative in-silico ADME study (opens in a new tab)Fijałkowska and Jurowski, Arch Toxicol 2025, DOI 10.1007/s00204-025-04170-5. Abstract and Excretion paragraph Par82 read through Europe PMC fullTextXML, especially the ADMETlab 3.0 output 1.182.PMC browser rendering returned CAPTCHA; actual full-text XML paragraphs were read through Europe PMC. Computational prediction, not a volunteer concentration-time study; the reported ~1.18 h is model-dependent.
- ACP 105 Overview — eight-week personal log (opens in a new tab)OPSSparta opening post and appended Days 1–3, Days 10–16, Weeks 3–8 and Final Overview; same-author replies adding antibiotic/intestinal-blockage context and a return hospital visit with symptom relief (rendered lines 169 and 184).Self-reported 21-year-old user, dose changes, illness, altered calories and ancillary supplements; no verified product or medical record. Initial kidney-inflammation account was later qualified by antibiotic/intestinal-blockage context and reported relief after a return visit; neither diagnosis nor drug causality is established. The ~8-hour statement is perceived coverage, not measured elimination.
Felt duration people report
~8 hours of perceived coverage in one log—not a verified half-life.
The author described quick morning stimulation followed by tiredness later. Other accounts range from improvement to absent effects or worse strength.
Single self-estimate with changing doses, sleep disruption and other confounders; not a reliable population duration, route-equivalent clock or redosing rule.
- ACP 105 Overview — eight-week personal log (opens in a new tab)OPSSparta opening post and appended Days 1–3, Days 10–16, Weeks 3–8 and Final Overview; same-author replies adding antibiotic/intestinal-blockage context and a return hospital visit with symptom relief (rendered lines 169 and 184).Self-reported 21-year-old user, dose changes, illness, altered calories and ancillary supplements; no verified product or medical record. Initial kidney-inflammation account was later qualified by antibiotic/intestinal-blockage context and reported relief after a return visit; neither diagnosis nor drug causality is established. The ~8-hour statement is perceived coverage, not measured elimination.
- My experience with ACP105 — strength-loss report and conflicting replies (opens in a new tab)HawkApprehensive505, June 19, 2024, OP (lines 20–23), dose clarification (line 75); opposing strength replies (50, 58, 91–92, 213) and week-5 negative report (120).OP corrects ambiguous opening dose to 15 mg/day in three 5 mg doses. Claimed testosterone units and mechanism speculation are not validated. Some positive replies stack ostarine; no controlled comparison.
What people say
- Anabolic:androgenic ratio (community-derived): Fitness write-ups commonly cite ~3.19:1 anabolic:androgenic-style ratio from early preclinical comparisons — not a standardized clinical label and should not be read like old AAS textbook ratios. forum
- Lean recomp (community): Modest lean/strength talk closer to ostarine / Andarine (S4) “feel” than heavy LGD/RAD bulk narratives. forum
- Dry / hard look (anecdote): Logs and vendor-style posts often emphasize less bloat / drier look than “wetter” androgens — heavily confounded by diet, sodium, and training. anecdote
- Strength continuity: Some logs note better pumps, mind-muscle connection, and compound-lift progress mid-cycle; others report only mild or no clear strength signal. forum
- Cut / lean bulk niche: Framed as useful for staying lean on a bulk or drying out on a cut rather than maximal mass-building. forum
- vs AC-262536: Comparison blogs rank ACP-105 as more “impactful” recomp compound and AC-262 as ultra-mild bridge/maintenance — uncontrolled ranking language. forum
- vs S4 / ostarine: Comparison threads often place subjective “feel” near Andarine/ostarine rather than LGD/RAD. forum
- Scale honesty: Without human LBM RCTs, expected gains are community-anecdotal and typically modest vs injectable AAS narratives. forum
- Muscle anabolism (animals): ACADIA preclinical and FASEB-class poster work describe potent anabolic effects on muscle in castrated / tissue-selectivity models. animal
- Bone anabolism (animals): Same early SARM profile claims bone anabolism alongside muscle effects preclinically. animal
- Prostate-sparing (animals): Minimal trophic effect on prostate in castrated animals vs strong muscle/bone signal — core “SARM selectivity” marketing claim. animal
- AR potency (in vitro): Described as as potent and efficacious as testosterone in in vitro AR assays without interaction at other hormone receptors in ACADIA discovery language. lab
- CNS / cognition (animals — not gym claims): Mouse work explores radiation-impaired performance, fear conditioning, and Alzheimer’s-model endpoints (alone or with ERβ agonist AC-186) — research story, not a bodybuilding benefit. animal
- Partial agonist framing: Discovery chemistry (Schlienger et al., J. Med. Chem. 2009) characterizes ACP-105 as a potent nonsteroidal SARM with partial agonist activity — community often contrasts this with full-agonist LGD-4033 talk. trial
Doses people talk about
- Animal → human “HED” meme: Mouse oral ~1 mg/kg/day (radiation/cognition models) is often allometrically hand-waved to ~11–12 mg/day for a ~175 lb (~79 kg) man in fitness write-ups — rough conversion, not a clinical dose. forum
- Common oral band: ~10–20 mg/day is the most repeated “user feedback / guide” range for adult male research discussion. forum
- Starter / lower band: ~10–12 mg/day (sometimes ~11–12 mg from the HED meme) when treated as a milder first SARM. forum
- “Need ~15 mg” talk: Some logs claim meaningful effects only around ~15 mg/day and up — selection bias and product quality unknown. forum
- Intermediate / upper recreational band: ~15–25 mg/day (some vendor-style or comparison charts go ~15–30 mg); higher end brings more suppression and androgenic-side anxiety in the same threads. forum
- Aggressive community ceiling talk: Occasional ~25–30 mg/day discussion; not supported by human safety trials and often paired with stronger stack partners. forum
- Female discussion (sparse): Often single-digit to ~5–10 mg/day with virilization caution; some “never over ~15 mg” blog rules; cycle length talk often shorter (~6–8 weeks). forum
- Split vs once-daily fight: Short in vitro / in silico half-life talk drives BID (or every ~8 h) split of total daily mg in many modern logs; older vendor memes of 12–16 h t½ push once-daily — both camps exist. forum
- Example split patterns (logs only): e.g. ~8.5 mg morning + ~8.5 mg later (~17 mg/day); or ~5 mg + ~5 mg on top of another SARM; or two equal halves of a 20 mg total. anecdote
- Pre-workout timing (anecdote): Some stack users take a portion ~30 min pre-training as a “preworkout SARM” habit — not PK-proven peak timing. anecdote
- Uncertainty: Labeled mg is unverified without third-party testing; “mg on bottle ≠ mg delivered.” forum
- Framing: Community / research-discussion ranges only — not medical advice, not prescriptions, not safety-validated for physique use. forum
- Animal doses (do not map 1:1): Mouse ~1 mg/kg/day (cognition/radiation); mouse AD models ~10 mg/kg/day for months with AC-186; equine oral doping studies use research mg/kg scales for metabolite hunting — none define gym protocols. animal
How it may feel
- Days 1–3: Sparse logs; some report mild headache, odd “awake but tired” energy, or nothing at all after first doses. forum
- Days 1–7: Little dramatic change for many; early “pump” or fullness notes are inconsistent; sleep disruption or restlessness appears in a subset of detailed logs. forum
- Week 1–2: Some claim slight gym fullness, endurance-style energy (not RAD-style aggression), or easier leanness if calories are controlled; many still see no clear signal. forum
- Weeks 2–3: Occasional “energizing” onset shortly after morning dose reported when users assume short coverage; night waking / nocturia appears in isolated logs. anecdote
- Weeks 3–4: Common informal checkpoint for strength, pumps, photos, and early suppression markers (morning wood, libido); some detailed 8-week logs call week ~4 the pump/strength peak. forum
- Weeks 4–6: Mid-cycle reassessment; older discussion weighs diet, protein, sleep and product authenticity before “more mg” when composition or performance signals are absent. A checked 6-week account instead described declining strength from week 3, with other users reporting the opposite; this is not a predictable response. forum
- Weeks 6–8: Common end of oral SARM templates; modest lean/strength talk if any; suppression and lipid/liver anxiety often rise here. forum
- Week 8+ / longer templates: 8–12 week “mild SARM” charts exist; multi-month ACP-only logs remain sparse. forum
Cycles people discuss
- Typical length: 6–8 weeks is the default oral SARM template most often copied for ACP-105. forum
- Shorter trials: 4–6 weeks for first runs, early lipid/libido/side stops, or low product confidence. forum
- Longer talk: 8–12 weeks appears in generic “mild SARM” guides; some older charts float 8–13 weeks — human safety data for those windows are effectively absent. forum
- Female length talk: Often 6–8 weeks at lower mg in the same sparse guides. forum
- Time off heuristic: Off-cycle ≥ on-cycle length is a frequent forum rule of thumb — not a clinical standard. forum
- PCT debate — “mild SARM” camp: Partial-agonist lore leads some to argue light or no SERM after short low-mg solo runs; bloodwork-first recovery talk is common. forum
- PCT debate — practical camp: Many still plan enclomiphene or tamoxifen-class SERM PCT after 6–8 week oral SARM blocks (example forum language: tamoxifen ~20 mg/day ~4 weeks; enclomiphene concurrent or post) — AAS-derived templates, not ACP-specific RCTs. forum
- On-cycle SERM/enclo co-use: Some modern logs run low-dose enclomiphene alongside ACP-105 (e.g. ~10 mg ACP + ~12.5 mg enclo-style talk) to blunt suppression — uncontrolled self-experimentation. forum
- Bloodwork talk: Pre, mid (~week 4), and post panels (total/free T, LH/FSH, estradiol, CBC, CMP/liver enzymes, fasting lipids) are the harm-reduction standard in SARM threads. forum
- Re-runs: Restarts after a break follow generic SARM seasonality; cumulative multi-year risk data for recreational ACP-105 do not exist. forum
- Bridge / cruise misuse: Continuous low-dose oral SARM “cruising” appears in broader SARM culture; no clinical support for chronic unsupervised exposure. forum
Timing
- Forum half-life memes: Vendor/blog posts often claim ~12–16 h and once-daily convenience; these claims generally lack primary human PK citations. forum
- User “coverage” talk: One detailed oral log describes an almost immediate energizing feeling after the morning dose and perceived fading around ~8 hours, alongside twice-daily use. That person's “half-life” wording describes subjective coverage, not a measured plasma half-life or validated reason to split a dose. anecdote
- Suppression lag: Libido, morning erections, mood, or “low T” feel often emerge mid-to-late cycle or after stop rather than day 1 — class pattern for oral SARMs. forum
- Human hepatocyte t½ (discovery chemistry): Schlienger et al. (J. Med. Chem. 2009) report ACP-105 (compound 1) half-life ~5.0 h in human hepatocytes (comparator analog ~8.4 h in the same assay) — metabolic stability in vitro, not full clinical plasma PK. lab
- In silico plasma t½: Multifaceted ADME modeling (Fijałkowska & Jurowski, Arch. Toxicol. 2025) predicts short half-life ~1.18 h (ADMETlab 3.0) — model-dependent, not measured volunteer PK. lab
- GI absorption (in silico): High predicted gastrointestinal absorption (SwissADME “High”; Percepta ~100%; pkCSM ~94%) supports oral research-chem route dominance. lab
- Lipophilicity / solubility (in silico): LogP roughly ~3.0–3.5; low aqueous solubility (LogS ~ −4.1 to −4.4) — oral absorption still predicted high but formulation/solvent quality may matter for liquids. lab
- Plasma protein binding (in silico): Strong PPB predicted (~77–99% depending on tool); free fraction often modeled as very low. lab
- BBB penetration (in silico + animal cognition context): Most ADME tools predict blood–brain barrier permeation; aligns with mouse CNS/cognition research use but is not a gym benefit claim. lab
- Metabolism: CYP3A4 is the most consistently predicted primary pathway (high substrate probability across tools); contributions from CYP2C9, CYP2C19, CYP2D6, and CYP1A2 appear with tool-to-tool disagreement; phase I hydroxylation and UGT/glucuronide pathways appear in equine/human metabolite work. lab
- Metabolite count (in silico / doping lit): ADME modeling discusses ~six predicted metabolites (M1–M6); equine in vivo work tentatively identified many more biotransformation products (hydroxylated, dihydroxylated, glucuronides) for anti-doping targeting. trial
- In silico tox flags (not human proof): Computational work notes possible DNA/protein interaction sites and potential cyanide-release pathways under certain metabolic assumptions — alerts for toxicology research, not measured clinical outcomes. lab
- Renal OCT2: pkCSM-class prediction: not an OCT2 substrate. lab
- Doping detection window: Parent and hydroxylated metabolites are analytical targets in sports drug testing; detection windows depend on dose, matrix, and method — not a “clearance diet” guarantee. trial
More on what it is
- Why people search it: Niche “milder / lean / dry” oral SARM alternative to LGD-4033 or RAD-140; far less forum volume than ostarine, RAD, or LGD. forum
- Research lens: Forum mg charts, 12–16 h half-life memes, and “milder than LGD” lore are discussion data — not verified human PK or head-to-head trials. forum
- What it is: Oral nonsteroidal SARM developed by ACADIA Pharmaceuticals; aniline-class AR modulator chemically related to AC-262536 and vosilasarm (RAD-140). trial
- Chemistry tags: Often listed as CAS 1048998-11-3; formula C16H19ClN2O (~290.8 g/mol); IUPAC-style name 2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile. trial
- Mechanism (simplified): Selective androgen-receptor partial agonist designed for muscle/bone anabolism with reduced prostate trophic activity in animals; discovery chemistry reported testosterone-like AR potency/efficacy without other hormone-receptor cross-talk in early assays. trial
- Evidence honesty: No recreational human RCTs for physique outcomes; published human data are essentially absent beyond doping-control metabolite work and in silico ADME — bodybuilding charts are extrapolations + sparse logs. trial
- Not this: Not a steroidal AAS by structure; not FDA-approved for muscle, HRT, or cognition; not “side-effect free”; not a peptide. trial
- Regulatory / sport: WADA has listed SARMs under “other anabolic agents” on the Prohibited List since 2008; ACP-105 appears in anti-doping metabolite and detection literature (including equine and human matrices). trial
Stacks
- Mild recomp classic: ACP-105 + ostarine (MK-2866) — very common “mild + mild” talk; example log ratios include ~7 mg ACP + ~17.5 mg ostarine, or ~10 mg ACP layered on ~20 mg ostarine. Additive suppression is often under-discussed. forum
- AC-262 / “ACE” adjacency: ACP-105 + AC-262536 appears in blend products and stack questions; both are ACADIA-lineage aniline SARMs. Community sometimes pairs ~10 mg ACP with ~20 mg AC-262 for recomp — pure vendor lore, not PK synergy data. forum
- Cut adjacency: ACP-105 + Cardarine (GW-501516) for “lean/hard” cuts; Cardarine is a PPARδ ligand, not a SARM, with its own separate safety discourse. forum
- Aggressive bulk talk: Occasional + LGD-4033 or RAD-140 — higher suppression, lipid, and side-effect concern than solo mild runs. forum
- S4 / Andarine comparisons: Sometimes rotated or compared rather than stacked; visual dryness talk overlaps. forum
- Enclomiphene co-therapy: Low-dose enclomiphene on-cycle or as PCT bridge to blunt HPTA shutdown narratives. forum
- Support folklore: NAC, omega-3 / krill oil, and generic “liver/lipid support” appear in logs — not ACP-specific efficacy evidence. anecdote
- Non-drug base: Progressive overload, high protein, sleep, and calorie control are credited whenever logs look good. forum
- PCT (generic SARM culture): Enclomiphene or tamoxifen-class SERMs after oral cycles — chart language only, not ACP-specific clinical care. forum
- Ratio honesty: Pre-mixed “stacks” and dual-SARM bottles vary by vendor; always treat stated ratios as untrusted until tested. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Partial agonist ≠ free pass: Fitness theory that partial agonism means less suppression than full-agonist LGD is unproven head-to-head in humans; higher recreational mg can still shut down feel. forum
- Lipids (class): HDL drop and unfavorable lipid shifts are standard oral-SARM discussion points; ACP-specific controlled lipid panels are thin. forum
- Liver enzymes (class): ALT/AST concern across gray-market orals; ACP-only causality is not established in trials, but harm-reduction culture still watches CMP. forum
- Androgenic residual: Acne, hair-shedding anxiety, prostate worry, and aggression talk appear at higher doses or in sensitive users — generally framed as milder than RAD/S-23 but not zero. forum
- CNS / sleep / energy oddities: Headache (sometimes early), insomnia or middle-of-night waking, and “wired but tired” notes appear in detailed personal logs. anecdote
- Kidney / organ account and follow-up: One public 8-week high-teens-mg log initially described hospital evaluation for kidney inflammation near cycle end. The same author later added antibiotic use and intestinal-blockage context, then described a return visit, MRI review and symptom relief after an enema. These are the author’s accounts, not verified medical records; neither the diagnosis nor ACP-105 causality is settled. The initial caution is retained with its later qualification. anecdote
- Source quality: Mislabeling, wrong concentration, underdosed liquids, and contamination are structural research-chem risks; doping labs sometimes find SARMs in products not labeled as such (class problem). forum
- Women’s virilization risk: Voice, hair, clitoral, and cycle changes are the usual SARM cautions at any androgenic agent — ACP-specific incidence unknown. forum
- Not risk-free: Sparse “good” logs and prostate-sparing animal data ≠ a human safety database. forum
- HPTA suppression: Expected class risk with dose and duration; community markers include reduced morning erections, libido drop, mood, and energy — documented subjectively even in “mild” partial-agonist framing. forum
- Regulatory / sport: Not FDA-approved as a dietary supplement or medicine for muscle; prohibited in tested sport; detection methods target parent and hydroxylated metabolites. trial
- Metabolite / tox unknowns: Multiple metabolites plus in silico alerts (including reactive-pathway flags) mean long-term human safety is uncharacterized. lab
- Drug–drug metabolism: Strong CYP3A4 substrate prediction implies possible interaction talk with strong CYP3A4 inhibitors/inducers — not mapped in clinical DDI trials for this molecule. lab
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.